Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue sarcoma
Cancer · 2025
DOI: 10.1002/cncr.35564 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Dina Braik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Sarcoma, Clinical Trials, Phase II as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
The clinical benefit of systemic anticancer therapies can be unclear despite positive trials, and outcomes may not translate to real‐world practice. This study evaluated the benefit of soft tissue sarcoma (STS) treatments using the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (MCBS) v1.1 and measured the robustness of STS trial results using Fragility Index (FI).
Methods
Database searches for adult phase II or III trials in advanced STS (January 1998–December 2023) were performed. Therapies with trial outcomes that met the criteria for MCBS were scored 1–5 (≥4 represents substantial clinical benefit). For randomized clinical trials with positive time‐to‐event endpoints, the number of additional events that would render results nonsignificant, FI, was calculated and expressed as a proportion of the experimental arm size (fragility quotient [FQ]). Higher FI/FQ implies more robust results.
Results
Among 194 trials, 19 (9.8%) were phase III. Most phase II trials (146/175; 83.4%) had single‐arm or non‐comparative design. Trials that were eligible for MCBS scoring ( n = 78; 40.2%) evaluated 56 different agents/regimens. Median MCBS score was 2. Only three agents/regimens (all cytotoxic therapies) had an MCBS score ≥4. Among 47 randomized clinical trials, 16 (8 phase II; 8 phase III) trials had positive outcomes. Median FI was 7 (range, 2–52) and 10 trials (62.5%) had an FQ < 10%, with median of 7% (range, 1%–59%).
Conclusions
Most systemic therapies in STS trials did not confer substantial clinical benefit per European Society of Medical Oncology‐MCBS. Additionally, positive randomized trials were often fragile. Novel STS therapy trials should use clinically meaningful endpoints and real‐world efficacy confirmation is essential, especially for less robust trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- CHU de Québec - Université Laval, Québec, Québec, Canada.
- Kingston Health Sciences Centre, Queens University, Kingston, Ontario, Canada.
ORCID-Profile: Dina Braik, Brooke E Wilson, Abdulazeez Salawu
Zitieren
APA
Braik, D., Lemieux, C., Wilson, B. E., Salawu, A., & Abdul Razak, A. R. (2025). Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue sarcoma. Cancer. https://doi.org/10.1002/cncr.35564
Vancouver
Braik D, Lemieux C, Wilson BE, Salawu A, Abdul Razak AR. Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue sarcoma. Cancer. 2025. doi:10.1002/cncr.35564
BibTeX
@article{Braik2025,
author = {Braik, Dina and Lemieux, Christopher and Wilson, Brooke E and Salawu, Abdulazeez and Abdul Razak, Albiruni R},
title = {Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue sarcoma},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35564}
}
EUVIMED